Suppr超能文献

《中国季节性流感疫苗接种技术指南(2020—2021年)》

[Technical guidelines for seasonal influenza vaccination in China (2020-2021)].

出版信息

Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Oct 10;41(10):1555-1576. doi: 10.3760/cma.j.cn112338-20200904-01126.

Abstract

Influenza virus infection is a respiratory infectious disease that can seriously affect human health. Influenza viruses can have frequent antigenic variation and changes, which can result in rapid and widespread transmission resulting in annual epidemics and outbreaks in places of public gathering such as schools, kindergartens and nursing homes. According to WHO estimation, seasonal influenza epidemics have caused an annually 3 to 5 million severe cases and 290 000 to 650 000 deaths globally. Pregnant women, young children, the elderly, and persons with chronic illnesses are at high risk for severe illness and death associated with influenza virus infection. Especially, COVID-19 pandemic might co-circulate with other respiratory infectious diseases such as influenza in the coming winter-spring season. Seasonal influenza vaccination is the most effective way to prevent influenza virus infection and complications from infection. Currently, China has licensed trivalent inactivated influenza vaccine (IIV3) which includes split-virus influenza vaccine and subunit vaccine, quadrivalent inactivated influenza vaccine (IIV4) which is split, and trivalent live attenuated influenza vaccine (LAIV3) which was newly licensed. Except for a few major cities, influenza vaccine is a category Ⅱ vaccine, which means influenza vaccination is voluntary, and recipients must pay for it. In 2018 and 2019, the China CDC issued the "Technical Guidelines for Seasonal Influenza Vaccination in China" . In the past year, new research evidences home and abroad have been published, and new seasonal influenza vaccine has been licensed in China. To strengthen the technical guidance for prevention and control of influenza and operational research on influenza vaccination in China, the National Immunization Advisory Committee (NIAC) Influenza Vaccination Technical Working Group (TWG), updated the 2019-2020 technical guidelines and compiled the "Technical guidelines for seasonal influenza vaccination in China (2020-2021)" . The main updates in this version include the following: First, new research evidences especially studies of China, including disease burden, effectiveness, Vaccine-avoidable disease burden, vaccine safety monitoring, and cost-effectiveness and cost-benefit. Second, policies and measures for influenza prevention and control issued by National Health Commission (PRC) in the past year. Thirdly, new type seasonal influenza vaccine licensed and issued in 2020-2021 in China. Fourth, northern hemisphere influenza vaccination composition for the 2020-2021 season which included trivalent and quadrivalent influenza vaccine. Fifth, Influenza vaccination recommendations for 2020-2021 influenza season. The recommendations described in this report include the following: Points of Vaccination clinics (PoVs) should provide influenza vaccination to all persons aged 6 months and above who are willing to be vaccinated and do not have contraindications. No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended, and appropriate product is available. Considering the situation of globally pandemic of COVID-19, to decrease the risk of influenza virus infection and minimize the impact on COVID-19 prevention and control, we recommend the following priority for seasonal influenza vaccination: healthcare workers, including clinical doctors and nurses, public health professionals, quarantine professionals; vulnerable groups living in nursing homes or welfare homes and staffs who take care those vulnerable groups; people work or stay in high population density places, such as teachers and students in kindergartens, primary and secondary school, prisoners and staffs of prisons; other high risk group of influenza, including adults ≥60 years of age, children aged 6-59 months, persons with specific chronic diseases, the family members and caregivers of infants <6 months of age, and pregnant women or women who plan to become pregnant during the influenza season. Children aged 6 months through 8 years require 2 doses of influenza vaccine administered a minimum of 4 weeks apart during their first season of vaccination for optimal protection. People whoever get IIV or LAIV all apply to the principle. If they were vaccinated in 2019-2020 influenza season or a prior season, 1 dose is recommended. People more than 8 years old require 1 dose of influenza vaccine. It is recommended that people receive their influenza vaccination by the end of October. Influenza vaccination should be offered as soon as the vaccination is available. For the people unable to be vaccinated before the end of October, influenza vaccination will continue to be offered for the whole season. Influenza vaccine is also recommended for use in pregnant women during any trimester. These guidelines are intended for use by staff members of the CDCs at all levels who work on influenza control and prevention, PoVs staff members, healthcare workers from the departments of pediatrics, internal medicine, and infectious diseases, and staff members of maternity and child care institutions at all levels. These guidelines will be updated periodically as new evidence becomes available.

摘要

流感病毒感染是一种可严重影响人类健康的呼吸道传染病。流感病毒可频繁发生抗原变异和变化,这可能导致其迅速广泛传播,从而在学校、幼儿园和养老院等公共聚集场所每年引发流行和暴发。据世界卫生组织估计,季节性流感流行每年在全球造成300万至500万重症病例以及29万至65万人死亡。孕妇、幼儿、老年人以及慢性病患者感染流感病毒后发生重症和死亡的风险较高。特别是,在即将到来的冬春季节,新冠疫情可能会与流感等其他呼吸道传染病共同流行。季节性流感疫苗接种是预防流感病毒感染及感染后并发症的最有效方法。目前,中国已批准的三价灭活流感疫苗(IIV3),包括裂解流感疫苗和亚单位疫苗;四价灭活流感疫苗(IIV4),为裂解疫苗;以及新批准的三价减毒活流感疫苗(LAIV3)。除少数大城市外,流感疫苗属于二类疫苗,即流感疫苗接种是自愿的,受种者需自费。2018年和2019年,中国疾病预防控制中心发布了《中国季节性流感疫苗接种技术指南》。过去一年,国内外发表了新的研究证据,中国也批准了新的季节性流感疫苗。为加强中国流感防控技术指导和流感疫苗接种工作研究,国家免疫规划专家咨询委员会(NIAC)流感疫苗接种技术工作组(TWG)更新了2019 - 2020技术指南,并编写了《中国季节性流感疫苗接种技术指南(2020 - 2021)》。本版主要更新内容如下:一是新的研究证据,特别是来自中国的研究,包括疾病负担、有效性、可避免疾病负担、疫苗安全性监测以及成本效益和成本效益分析;二是国家卫生健康委员会(中华人民共和国)过去一年发布的流感防控政策和措施;三是2020 - 2021年中国批准上市的新型季节性流感疫苗;四是2020 - 2021年北半球流感疫苗接种组分,包括三价和四价流感疫苗;五是2020 - 2021年流感季节的流感疫苗接种建议。本报告中的建议如下:接种门诊应向所有愿意接种且无禁忌证的6月龄及以上人群提供流感疫苗接种服务。对于有多种已批准、推荐且适用产品的人群,不特别推荐某一种流感疫苗产品优于另一种。考虑到新冠疫情全球大流行的情况,为降低流感病毒感染风险并尽量减少对新冠防控的影响,我们建议季节性流感疫苗接种的优先顺序如下:医护人员,包括临床医生和护士、公共卫生专业人员、检疫专业人员;居住在养老院或福利院的弱势群体以及照顾这些弱势群体的工作人员;在人口密集场所工作或停留的人员,如幼儿园、中小学的教师和学生、监狱囚犯及监狱工作人员;其他流感高危人群,包括≥60岁的成年人、6 - 59月龄儿童、患有特定慢性病的人员、<6月龄婴儿的家庭成员和照料者,以及流感季节期间的孕妇或计划怀孕的女性。6月龄至8岁儿童在首次接种流感疫苗的季节需要接种2剂,间隔至少4周,以获得最佳保护。接种IIV或LAIV的人群均适用此原则。若在2019 - 2020流感季节或之前的季节已接种过,建议接种1剂。8岁以上人群需要接种1剂流感疫苗。建议在10月底前完成流感疫苗接种。一旦有疫苗供应应尽快提供接种服务。对于10月底前无法接种的人群,整个流感季节均可继续提供接种服务。也建议在孕期的任何阶段为孕妇接种流感疫苗。本指南供各级从事流感防控工作的疾病预防控制中心工作人员、接种门诊工作人员、儿科、内科和传染病科医护人员以及各级妇幼保健机构工作人员使用。随着新证据的出现,这些指南将定期更新。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验